130 related articles for article (PubMed ID: 12501127)
21. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
22. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).
Zembower DE; Liao S; Flavin MT; Xu ZQ; Stup TL; Buckheit RW; Khilevich A; Mar AA; Sheinkman AK
J Med Chem; 1997 Mar; 40(6):1005-17. PubMed ID: 9083491
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
25. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
Currens MJ; Mariner JM; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
[TBL] [Abstract][Full Text] [Related]
26. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
Gewurz BE; Jacobs M; Proper JA; Dahl TA; Fujiwara T; Dezube BJ
J Infect Dis; 2004 Dec; 190(11):1957-61. PubMed ID: 15529260
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
[TBL] [Abstract][Full Text] [Related]
29. Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor.
Hanna L
BETA; 1999 Apr; 12(2):8-9. PubMed ID: 11366704
[TBL] [Abstract][Full Text] [Related]
30. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
Ferry JJ; Herman BD; Carel BJ; Carlson GF; Batts DH
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):252-9. PubMed ID: 9665503
[TBL] [Abstract][Full Text] [Related]
33. [Anti-HIV activities of HIV-1 reverse transcriptase inhibitor racemic 11-demethyl-calanolide A].
Peng ZG; Chen HS; Wang L; Liu G
Yao Xue Xue Bao; 2008 May; 43(5):456-60. PubMed ID: 18717330
[TBL] [Abstract][Full Text] [Related]
34. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B.
Galinis DL; Fuller RW; McKee TC; Cardellina JH; Gulakowski RJ; McMahon JB; Boyd MR
J Med Chem; 1996 Oct; 39(22):4507-10. PubMed ID: 8893846
[TBL] [Abstract][Full Text] [Related]
36. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
[TBL] [Abstract][Full Text] [Related]
38. Calanolide looks promising.
AIDS Patient Care STDS; 2000 Apr; 14(4):225-6. PubMed ID: 10806645
[No Abstract] [Full Text] [Related]
39. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
40. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
